Association of serum NOx level with clustering of metabolic syndrome components in middle-aged and elderly general populations in Japan

Environmental Health and Preventive Medicine

Volumn 13, Issue 1, 2008, Pages 36-42

  Ueyama, Jun ^a,b   Kondo, Takaaki ^a   Imai, Ryota ^a   Kimata, Akiko ^a   Yamamoto, Kanami ^a   Suzuki, Koji ^c   Inoue, Takashi ^c   Ito, Yoshinori ^a   Miyamoto, Ken Ichi ^b   Hasegawa, Takaaki ^d   Hamajima, Nobuyuki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

^d AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Analysis of covariance; Cyclic guanosine 3 5 Monophosphate (cGMP); Metabolic syndrome; Nitric oxide

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; NITRITE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; POPULATION RESEARCH; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

EID: 42049089974     PISSN: 1342078X     EISSN: 13474715     Source Type: Journal    
DOI: 10.1007/s12199-007-0001-1     Document Type: Article

References (25)

1. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28:2745-9.
2. Miyatake N, Kawasaki Y, Nishikawa H, Takenami S, Numata T. Prevalence of metabolic syndrome in Okayama prefecture, Japan. Intern Med. 2006;45:107-8.
3. National Cholesterol Educaton Program (NCEP) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III (updated 2004). Circlation 106:3143-221.
4. Stuehr DJ. Enzymes of the l-arginine to nitric oxide pathway. J Nutr. 2004;134:2748S-51S.
5. Moncada S, Palmer RM, Higgs EA. The discovery of nitric oxide as the endogenous nitrovasodilator. Hypertension. 1988;12:365-72.
6. Binion DG, Fu S, Ramanujam KS, Chai YC, Dweik RA, Drazba JA, et al. iNOS expression in human intestinal microvascular endothelial cells inhibits leukocyte adhesion. Am J Physiol. 1998;275:G592-603.
7. Zuckerbraun BS, Stoyanovsky DA, Sengupta R, Shapiro RA, Ozanich BA, Rao J, et al. Nitric oxide-induced inhibition of smooth muscle cell proliferation involves S-nitrosation and inactivation of RhoA. Am J Physiol Cell Physiol. 2007;292:C824-31.
8. Thippeswamy T, McKay JS, Quinn JP, Morris R. Nitric oxide, a biological double-faced janus - is this good or bad? Histol Histopathol. 2006;21:445-58.
9. Cook S, Hugli O, Egli M, Vollenweider P, Burcelin R, Nicod P, et al. Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. Swiss Med Wkly. 2003;133:360-3.
10. Tsutsui M, Shimokawa H, Morishita T, Nakashima Y, Yanagihara N. Development of genetically engineered mice lacking all three nitric oxide synthases. J Pharmacol Sci. 2006;102:147-54.
11. Konukoglu D, Serin O, Turhan MS. Plasma leptin and its relationship with lipid peroxidation and nitric oxide in obese female patients with or without hypertension. Arch Med Res. 2006;37:602-6.
12. Kondo T, Ueyama J, Imai R, Suzuki K, Ito Y. Association of abdominal circumference with serum nitric oxide concentration in healthy population. Environ Health Prev Med. 2006;11:321-5.
13. Cui R, Iso H, Pi J, Kumagai Y, Yamagishi K, Tanigawa T, et al. Metabolic syndrome and urinary cGMP excretion in general population. Atherosclerosis. 2007;190:423-8.
14. Kitaichi K, Wang L, Takagi K, Iwase M, Shibata E, Nadai M, et al. Decreased antipyrine clearance following endotoxin administration: in vivo evidence of the role of nitric oxide. Antimicrob Agents Chemother. 1999;43:2697-701.
15. Ko GT, Cockram CS, Chow CC, Yeung V, Chan WB, So WY, et al. High prevalence of metabolic syndrome in Hong Kong Chinese-comparison of three diagnostic criteria. Diabetes Res Clin Pract. 2005;69:160-8.
16. Clini E, Volterrani M, Pagani M, Bianchi L, Porta R, Gile' LS, et al. Endogenous nitric oxide in patients with chronic heart failure (CHF): relation to functional impairment and nitrate-containing therapies. Int J Cardiol. 2000;73:123-30.
17. Maejima K, Nakano S, Himeno M, Tsuda S, Makiishi H, Ito T, et al. Increased basal levels of plasma nitric oxide in Type 2 diabetic subjects. Relationship to microvascular complications. J Diabetes Complications. 2001;15:135-43.
18. Savino A, Pelliccia P, Schiavone C, Primavera A, Tumini S, Mohn A, et al. Serum and urinary nitrites and nitrates and Doppler sonography in children with diabetes. Diabetes Care. 2006;29:2676-81.
19. Rydén M, Elizalde M, van Harmelen V, Ohlund A, Hoffstedt J, Bringman S, et al. Increased expression of eNOS protein in omental versus subcutaneous adipose tissue in obese human subjects. Int J Obes Relat Metab Disord. 2001;25:811-5.
20. Osawa M, Hayashi T, Nomura H, Funami J, Miyazaki A, Ignarro LJ, et al. Nitric oxide (NO) is a new clinical biomarker of survival in the elderly patients and its efficacy might be nearly equal to albumin. Nitric Oxide. 2007;16:157-63.
21. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res. 2006;98:1352-64.
22. Arteaga E, Villaseca P, Rojas A, Arteaga A, Bianchi M. Comparison of the antioxidant effect of estriol and estradiol on low density lipoproteins in post-menopausal women. Rev Med Chil. 1998;126:481-7.
23. Zeballos GA, Bernstein RD, Thompson CI, Forfia PR, Seyedi N, Shen W, et al. Pharmacodynamics of plasma nitrate/nitrite as an indication of nitric oxide formation in conscious dogs. Circulation. 1995;91:2982-8.
24. Wever KE, Masereeuw R, Miller DS, Hang XM, Flik G. Endothelin and calciotropic hormones share regulatory pathways in multidrug resistance protein 2 (Mrp2-) mediated transport. Am J Physiol Renal Physiol. 2007;292:F38-46.
25. Alessio L, Berlin A, Dell'Orto A, Toffoletto F, Ghezzi I. Reliability of urinary creatinine as a parameter used to adjust values of urinary biological indicators. Int Arch Occup Environ Health. 1985;5:99-106.